Akero Therapeutics, Inc. (AKRO)

Market Cap	3.95B
Revenue (ttm)	n/a
Net Income (ttm)	-237.22M
Shares Out	76.23M
EPS (ttm)	-3.74
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	816,644
Open	51.46
Previous Close	50.58
Day's Range	51.09 - 52.74
52-Week Range	17.86 - 58.40
Beta	-0.11
Analysts	Strong Buy
Price Target	75.86 (+46.34%)
Earnings Date	Mar 3, 2025

About AKRO

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manuf...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 20, 2019
• Employees: 56
• Stock Exchange: NASDAQ
• Ticker Symbol: AKRO
• Website: https://akerotx.com

Analyst Forecast

According to 9 analysts, the average rating for AKRO stock is "Strong Buy." The 12-month stock price forecast is $75.86, which is an increase of 46.34% from the latest price.

Price Target

$75.86

(46.34% upside)

Analyst Consensus: Strong Buy